Abstract: Prolactin (PRL) hormone plays an important role in the development of the mammary gland and terminal differentiation of the mammary epithelial cells. While initial studies suggested that PRL may contribute to the development of breast cancer through PRL/prolactin receptor (PRLR) autocrine function, mounting evidence indicate a different role for PRL, highlighting this hormone as a regulator of epithelial plasticity and as a potential tumor suppressor. To gain further insights into the role of PRL in human breast carcinogenesis, immunohistochemistry analyses of PRLR protein expression levels using tissue microarray of 102 cases were done in comparison with various clinical/pathologic parameters and molecular subtypes. In addition, gene expression level of PRLR was also evaluated in relation to intrinsic molecular subtypes, tumor grade, and patient outcome using GOBO database for 1881 breast cancer patients. Interestingly, PRLR expression was found to be significantly downregulated in invasive breast cancer (21.4%) in comparison with normal/benign (80%) and in situ carcinoma (60%) (P = 0.003498). Moreover, PRLR expression was associated with lymph node negativity and low-grade welldifferentiated tumors. PRLR expression was strongest in luminal A subtype, and was virtually undetectable in the worse prognosis triple-negative breast cancer subtype (P = 0.00001). Furthermore, PRLR expression was independent of ER, PR, HER-2, and P53 status. Finally, PRLR expression was significantly (P < 0.01) associated with prolonged distant metastasis-free survival in breast cancer patients. In conclusion, our results highlight PRLR as an independent predictor of favorable prognosis in human breast cancer.
B
reast cancer is a heterogenous disease in its molecular, pathologic, and therapeutic features. 1 Variations in behavior and differences in response to therapy and clinical outcome still are seen in patients with similar clinical and pathologic characteristics. 2, 3 Further classification of breast cancer according to different molecular subtypes including, luminal A, luminal B, HER-2 enriched, basal like, and normal like was recently achieved. 4 Indeed, luminal A comprise mostly differentiated and best prognosis tumors. Whereas, basal subtype is more frequently associated with organ metastasis, and has a poor prognosis. 5 PRL hormone is well known to produce a wide spectrum of biological functions associated with reproduction, behavior, and immunomodulation. While the role of PRL in the normal development of the mammary gland and lactation is well established, its role in breast carcinogenesis is still not well defined. Previous studies have suggested that PRL pathway plays a role in the development of breast cancer through PRL/PRLR autocrine function. [6] [7] [8] [9] PRL can work as a local growth factor and can lead to breast cancer cell proliferation, cell migration, and cell survival. In contrast, other studies questioned the role of PRL as a likely promoter of breast carcinogenesis. Indeed, PRL signaling through PRLR and Jak2 kinase was found to suppress epithelial-mesenchymal-transition EMT process and the invasive properties of breast cancer cells. 10 Moreover, PRL and PRLR expression was found to be low or undetectable in breast cancer cases. 11 Together these studies highlight the complexity in defining the role of PRL in breast cancer and emphasize the need to further evaluate its function in breast tumorigenesis.
Here we examined PRLR expression in human breast cancer cases in relation to classic clinical and pathologic as well as molecular prognostic parameters. Our results indicate that PRLR expression is decreased in invasive carcinoma, whereas its expression is highest in well-moderately differentiated and lymph node (LN)-negative tumors. Furthermore, with respect to the various breast cancer molecular subtypes, our results clearly indicate that PRLR expression is highest in the least aggressive luminal A subtype, whereas virtually undetectable in invasive triple-negative breast tumors. Moreover, PRLR expression was found to be independent of estrogen receptor (ER),progesterone receptor (PR), HER-2, or P53 status. Finally, correlation analysis of PRLR gene expression with clinical patient outcome showed a significant association between higher PRLR expression and prolonged distant metastasis-free survival (DMFS) in breast cancer patients. Together our results highlight PRLR as an independent indicator of better prognosis in breast cancer further emphasizing its protective role.
MATERIALS AND METHODS

Cell Culture
The breast cancer cell line T47D, used as a positive control for IHC studies (Fig. S1 
Immunohistochemistry
Formalin-fixed paraffin-embedded slides were baked for 30 minutes at 551C, followed by deparaffinization then rehydration. Heat-induced antigen retrieval was performed in sodium citrate 10 mM, pH 6.0 buffer. The slides were incubated in hydrogen peroxide block for 10 minutes, followed by Ultra V Block for 5 minutes. Slides were incubated with rabbit polyclonal antibody against PRLR long form (H-300) (#sc-20992; Santa Cruz, Dallas, Texas). UltraVision LP Detection System HRP Polymer and DAP Plus Chromogen (Thermo Fisher Scientific, Fremont, CA) was used for detection. The TMA slides were scanned using Aperio XT slide scanner (Leica Biosystems, Concord, Ontario).
Immunohistochemistry Scoring
We used a semiquantitative method for PRLR scoring. A score of 0 indicates undetectable PRLR expression; +1, <10% of tumor cells; +2, 10% to 50% of tumor cells; and +3, is >50% of tumor cells. Both scores 0 and +1 were considered negative. The staining was considered positive only if there is membranous and/or granular cytoplasmic staining in malignant cells. The intensity of staining was also classified into weak, intermediate, and strong. The slides were evaluated independently by 2 investigators blinded to the clinical data. If there is any discordance, simultaneous examination was performed to solve the difference.
The ER and PR data were classified according to Allred score. Scores Z3 were considered positive. HER-2 expression was classified according to HercepTest. P53 status was defined as positive if the percentage of cells with antibody nuclear staining was Z10%.
Gene Set Analysis (GSA)
We used Gene expression-based Outcome for Breast cancer Online (GOBO) database to study the association between PRLR and different well-known clinical and pathologic prognostic parameters. 
Statistical Analysis
The results of PRLR immunoreactivity were tabulated and the relation between PRLR expression and association with different clinical and pathologic parameters were analyzed using the w 2 test.
RESULTS
Prolactin Receptor Expression is Downregulated in Invasive Carcinoma
Tumorigenesis is a multistep process involving the transformation and progression of normal to malignant cells. To evaluate the role of PRLR in this process, we studied PRLR expression in normal, benign, in situ, and invasive breast carcinomas in a TMA of 102 human breast cancer cores (Fig. S2 , Supplemental Digital Content 2, http://links.lww.com/AIMM/A72). Interestingly, our analysis revealed a significant downregulation of PRLR expression in invasive carcinoma in comparison with normal/benign and in situ carcinoma (Table 1 and Figs. 1A-C). Indeed, whereas 80% of benign and 60% of carcinoma in situ cases show positive PRLR staining, only 21% of invasive breast cancer cases show positive staining (P = 0.0034). The staining pattern was seen either as granular cytoplasmic in most of the cases or membranous in few cases (Fig. 1D ). Of note, most of the positive normal/benign cases (80%) showed moderate PRLR expression, whereas only 8.64% showed that pattern of immunoreactivity in the invasive breast cancer cores (Table 1) . Together, our data indicate that PRLR expression is downregulated in invasive breast carcinoma, further supporting the notion that the PRL pathway is likely to play a protective role in breast tumorigenesis.
Prolactin Receptor Expression in Various Molecular Subtypes of Breast Cancer
Molecular subtypes of breast cancer which includes luminal like, HER-2 enriched, basal like, and normal like may provide further prognostic value in relation to patient outcome. 4 We used the TMA described above to study the relation between PRLR expression and the different molecular subtypes of breast cancer. Within the 102 cores, we were able to reclassify 78 cases according to immunohistochemical panel including ER, PR, HER-2, and Ki-67 expression as surrogate of breast cancer molecular subtypes. 12 The cases were divided into luminal A (20 cases), luminal B (21 cases), HER-2 enriched (26 cases), and triple negative (11 cases) (Fig. S3 , Supplemental Digital Content 3, http://links.lww.com/AIMM/A73). Importantly, PRLR expression was positive in 30% of luminal A subtype cores. Within the luminal B subtype, PRLR positivity was observed in 28.5% of the cases. Moreover, PRLR was found to be expressed in 23.08% of the HER-2-enriched subtype cases. Interestingly, there was no detectable PRLR immunoreactivity in the triple-negative cases (Table 1) . To further assess the correlation between PRLR expression and the different breast cancer molecular subtypes, we assessed PRLR gene expression level using GSA of GOBO database. This database contains information on 1881 breast cancer cases that have been classified by 2 different classification methods (PAM50 and Hu et al). 13 Interestingly, and in agreement with the IHC and protein data, we found a highly significant association of PRLR gene expression with luminal A subgroup and least association with basal-like subgroup (Pr0.00001) (Figs. 2A,  B) . Altogether, these results indicate that PRLR expression is associated with the least aggressive breast cancer luminal A subtype and loss of its expression is an indicator of aggressive breast cancer phenotype.
Prolactin Receptor Expression is Associated With LN-negative and Well-moderately Differentiated Breast Cancer
Tumor stage at diagnosis is regarded as the major predictor of survival in breast cancer patients. Advanced stages (large tumor size and LN involvement) are associated with worse prognosis and least chance of survival. [14] [15] [16] Thus, we next investigated and compared PRLR expression levels with tumor stage, grade, size, and LN involvement (Fig. S3 , Supplemental Digital Content 3, http://links.lww.com/AIMM/A73) ( Table 1) . Importantly, patients with in situ carcinoma showed PRLR expression in 60% of cases (stage 0). Whereas PRLR immunoreactivity was found in only 21.57% in patients with stage I and II and 21.21% in stage III. This indicates that PRLR expression is lost early in the process of cancer progression.
LN involvement is considered as a key determinant in assessing tumor metastatic potential. 17 Moreover, it is well known that LN negativity is an important good prognostic indicator of overall survival and relapse-free survival. To investigate the role of PRLR in relation to tumor metastatic potential, we studied the association between PRLR expression and LN status. Interestingly, we observed a nearly significant association of PRLR expression with LN-negative tumors (31.25%) in comparison with LN-positive tumors (14.63%) (P = 0.060).
Tumor grade is another well-established parameter in determining prognosis and patient outcome. Therefore, we next examined PRLR expression in relation to tumor grade. Importantly, PRLR expression was nearly double in well-moderately differentiated tumors (23.53%) in comparison with poorly differentiated tumors (13.33%). Notably, most of the moderate PRLR staining (85%) was seen in the well-moderately differentiated tumors.
To further elaborate the above findings, we analyzed PRLR gene expression in the 1881 breast cancer cases of GOBO database. Importantly, our analysis showed a highly significant correlation between PRLR expression and well-moderately differentiated tumors in comparison with poorly differentiated tumors (Pr0.00001) (Fig. 3) . Altogether our data indicate that PRLR expression is mainly associated with well-established good prognostic clinical and pathologic parameters including well-moderately differentiated tumors, LN negativity, and luminal subtypes.
Prolactin Receptor Expression in Relation to Classic Biomarkers
We next investigated the association between PRLR expression and the expression of breast cancer biomarkers classically used to provide prognostic information ( À tumors. P53 is well-known tumor suppressor gene that normally has a short half-life. Mutations of P53, known to be associated with poor outcome, will lead to stabilization and accumulation of P53 in the nucleus of tumor cells. 18 Here we evaluated the correlation between PRLR expression and P53. P53 expression was considered as positive if Z10% of cells showed nuclear stain. 19 There was no statistical association between PRLR expression and P53 status (P = 0.531774) ( Table 2 ). These data together indicate that PRLR is an independent marker of favorable prognosis and suggest its potential use for stratification of patients for prognostic and therapeutic purposes.
Prolactin Receptor Expression is Associated With Prolonged DMFS in Patients With Breast Cancer
To assess the correlation between PRLR expression and clinical outcome for the different breast cancer clinical, pathologic, and molecular subgroups, we used GOBO database of 1379 breast cancer human samples using DMFS as an endpoint (Fig. 4A) . Interestingly, both LN-negative and LN-positive tumors showed more prolonged DMFS with higher PRLR expression (P < 0.00001 and P = 0.00048, respectively). Moreover, ER + and its subgroup ER + with LN-negative tumors also showed the same pattern (P = 0.00392) (Fig. 4B) . In addition, among the molecular subtypes, luminal B subgroup showed the most significant association between higher PRLR expression and prolonged DMFS (Fig. 4B) . Finally, PRLR higher expression showed the same favorable outcome when all patients or untreated patients only were considered (P < 0.00001 and P = 0.00156, respectively) (Fig. 4B ). Altogether these results indicate that PRLR expression is significantly associated with prolonged DMFS and better clinical outcome in breast cancer patients.
DISCUSSION
While the role of PRL signaling in promoting the development and the differentiation of the mammary gland is well understood, its role in breast carcinogenesis remains unclear and controversial. In this study, we compared PRLR expression levels with various clinical, pathologic, and molecular parameters using TMA, as well as publically available gene profiling database of breast cancer human samples. Our results revealed a significant decrease in PRLR gene expression and protein levels in invasive breast cancer. In addition, we observed that PRLR-positive cases are of low-grade tumors and LN negative. Furthermore, we found that PRLR was expressed in 30% of luminal A tumors, whereas its signal is absent in triple-negative tumors. Moreover, PRLR expression was associated with better clinical outcome in patients with breast cancer. All these findings support the use of PRLR as a favorable prognostic marker in breast cancer.
There is conflicting information with regard to the expression levels of PRLR in human breast cancer. While it was shown that PRLR to be expressed in more than two thirds of breast carcinoma, another study indicated that PRLR was expressed in only 3% of a panel of 160 breast cancer cases. 20, 21 Our previous work showed undetectable PRLR expression using a panel of 100 invasive breast cancer cases. 11 In agreement with these findings in this study, we found a clear decrease in PRLR expression in breast cancer cases compared with normal tissue. Altogether these results indicate that expression of the receptor is generally downregulated in human breast cancer cases. Therefore, we propose that PRL signaling is more likely to play a protective and suppressive role in breast cancer rather than promoting role.
Invasion to the adjacent axillary LN is regarded as one of the most important prognostic factor in breast cancer. 16 The 5-year survival of breast cancer patient is significantly reduced in LN-positive tumor in comparison with LN-negative tumors. 14 With respect to PRL pathway, we have previously shown that PRL signaling regulates epithelial plasticity resulting in suppression of EMT process and invasive behavior of breast cancer cells. 10 For that reason, we investigated PRLR expression in relation to LN status. Our data showed a nearly significant association between positive PRLR expression and LN-negative tumors. This strongly supports the favorable role of PRL and its pathway as a potential invasion suppressor hormone in breast cancer.
Tumor grade is another well-know prognostic parameter in breast cancer and patients with low-grade tumors show better prognosis in comparison with patients with high-grade tumors. As PRL signaling is important in inducing differentiation of mammary epithelial cells, we next investigated the association between PRLR expression with tumor grade. Our data revealed a significant association between PRLR positivity and low-intermediate grade tumors that usually associate with good prognosis. This finding is also in agreement with previous study showing a significant correlation between positive PRLR expression and well-moderate differentiated tumor. 22 These data highlight the prodifferentiation role of PRL pathway in the normal and malignant mammary tissue.
Different types of breast cancer show different biological, pathologic, and even clinical outcomes. 1 This is the first report to analyze PRLR expression levels in relation to the different molecular subtypes of breast cancer. PRLR expression was still preserved in better differentiated and the best prognostic luminal A subgroup. Conversely, there was no PRLR immunoreactivity in all the triple-negative tumors that are known to be aggressive and usually linked to EMT, stemness, and metastasis. 23 These results further support the notion that PRL play a prodifferentiative role and an EMT inhibitor in breast cancer. Our results showed no significant association between PRLR expression and ER, PR, or HER-2 status. This differ from previous reports that showed that ER-a and PRLR are coexpressed in breast cancers, 24 but in agreement with a recent study showing PRLR expression to be independent of ER status. 22 These results together support the view that PRLR expression is an independent prognostic marker.
We also evaluated the impact of PRLR gene expression on breast cancer patients clinical outcome using DMFS as an endpoint. Higher PRLR gene expression was significantly associated with prolonged DMFS in both LNnegative and LN-positive tumors and ER + tumors. Interestingly, the most significant association between PRLR gene expression and prolonged DMFS was observed in the luminal B subgroup, which usually is associated with early relapse and poor prognosis. 25 This highlights the need for future studies examining the role of PRL as a prognostic and therapeutic tool in this subgroup. Finally, when all patients or untreated patients were considered, the same favorable outcome of PRLR expression was observed. These data uncover a powerful and independent role of PRLR expression as a prognostic marker for DMFS. Altogether, the analyses described here indicate that PRLR expression is significantly associated with prolonged DMFS and better clinical outcome in breast cancer patients.
In conclusion, our study reveals that expression of the PRLR can be used as independent good prognostic marker for breast cancer patients. In addition, these findings highlight the need for larger clinical studies to examine the clinical relevance and the possible therapeutic role of PRL and its signaling pathway in the management of breast cancer.
